Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody

CAR-T Digest - August 2020

15 September 2025: Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody

Biocytogen announced that Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen for use in a novel ADC candidate
The antibody was created using Biocytogen’s proprietary RenMice platform, offering high affinity, low immunogenicity, and favorable developability
Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies from this antibody, targeting areas of high unmet clinical need in cancer
The agreement stems from a previous research collaboration and option deal between the two companies to advance antibody components for ADC development
Biocytogen will receive an upfront payment, and is eligible for development, regulatory and commercial milestone payments, plus single-digit royalties on net sales